JAMA Data Brief: GLP-1 receptor agonist use among US adults with type 2 diabetes nearly doubled between 2019 and 2022, primarily driven by semaglutide and dulaglutide
If this revolutionary treatment could help you live longer by fighting obesity, diabetes, and arthritis all at once, whats standing in your way
Monitor your weight and symptoms and be prepared with a game plan of how to address challenges that arise
For those patients, Ro takes on benefits verification and works with a partner to optimize prior authorizations and then clearly communicates treatment options, coverage details, and transparent cost estimates
Nausea is the most frequently reported and affects approximately 40 to 50 percent of patients, particularly during dose escalation
In the current study, we show that QMP engineering for enhanced pH-dependent FcRn engagement extends the plasma half-life of albumin fusion proteins far beyond that achieved by using WT albumin